V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10416507 | 10041250 | 1.8 | 69.2 | Disease modification (D) | 2017-04-26 | 2017-05-01 | null | N | null | FLAIR TRIAL | 101510388 |
| 10416573 | 10041251 | 1.81 | 64 | Palliative (P) | 2018-01-24 | 2018-01-31 | IDARUBICIN + METHOTREXATE + VINCRISTINE | 02 | null | AVELUMAB + AXITINIB | 101836152 |
| 10416647 | 10041252 | 1.81 | 73.9 | Disease modification (D) | 2017-12-23 | 2018-01-08 | PEG INTERFERON | N | N | GDP | 100367459 |
| 10416763 | 10041253 | 1.6 | 67.8 | Adjuvant (A) | 2018-11-17 | 2018-11-17 | CETUXIMAB + RT | N | null | DABRAFENIB | 101078990 |
| 10416813 | 10041254 | 1.75 | 87 | 03 | 2018-12-30 | 2018-12-30 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | N | AZACITIDINE + VENETOCLAX | 100962091 |
| 10417018 | 10041257 | 1.77 | 77 | Palliative (P) | 2020-01-02 | 2020-01-02 | Radium 223 | N | N | CAPECITABINE + IRINOTECAN | 101165440 |
| 10417036 | 10041258 | 1.83 | 75 | 03 | 2015-11-03 | 2015-12-27 | PLATO Trials | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101532615 |
| 10417168 | 10041259 | 0 | 110 | Adjuvant (A) | null | 2016-07-06 | FEC + DOCETAXEL + TRASTUZUMAB | N | N | OXALIPLATIN + MDG | 101054311 |
| 10417173 | 10041260 | 1.76 | 71.7 | Adjuvant (A) | 2017-10-15 | 2017-10-15 | MELPHALAN + THALIDOMIDE | 02 | null | ECX | 100458555 |
| 10417251 | 10041261 | 1.69 | 55 | Palliative (P) | 2018-10-26 | 2018-10-26 | STAMPEDE TRIAL | 02 | null | OBINUTUZUMAB + VENETOCLAX | 101112452 |
| 10417678 | 10041264 | 1.81 | 67.5 | 03 | 2017-10-19 | 2017-10-30 | Ixazomib + Lenalidomide | 02 | N | CISPLATIN + PEMETREXED | 100734630 |
| 10417686 | 10041265 | 1.65 | 78.3 | null | 2016-10-13 | 2016-11-02 | Atezolizumab | 02 | null | AML19 TRIAL | 100047383 |
| 10417777 | 10041266 | 1.6 | null | Unknown (U) | 2018-08-06 | 2018-08-06 | PARTNER Trial | N | N | EC | 100083001 |
| 10417826 | 10041268 | 1.75 | 77.2 | 03 | 2016-06-17 | 2016-07-08 | CETUXIMAB + RT | 02 | N | FCR | 100043686 |
| 10418027 | 10041271 | 1.63 | 87.6 | Curative (C) | 2018-04-06 | 2018-04-23 | Cisplatin + Pemetrexed | 01 | N | FEC | 101655532 |
| 10418156 | 10041273 | 1.63 | 65.4 | Curative (C) | 2017-09-30 | 2017-10-01 | Raltitrexed | null | N | PARTNER TRIAL | 100447057 |
| 10418182 | 10041274 | 1.6 | 84.2 | Palliative (P) | null | 2017-07-09 | Atezolizumab | 01 | N | CARBOPLATIN + EPIRUBICIN | 100395833 |
| 10418201 | 10041275 | 1.78 | 77.5 | null | 2019-07-14 | 2019-08-18 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | RITUXIMAB + VENETOCLAX | 100024914 |
| 10418210 | 10041276 | 1.78 | 78.2 | Palliative (P) | 2018-06-15 | 2018-06-15 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | 02 | N | OBINUTUZUMAB + VENETOCLAX | 101211663 |
| 10418246 | 10041277 | null | 75.1 | Curative (C) | 2018-08-07 | 2018-09-04 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | RIALTO TRIAL | 100298252 |
| 10418399 | 10041281 | 1.62 | 97 | Disease modification (D) | 2021-09-10 | 2021-09-29 | Oxaliplatin + Modified de Gramont | 02 | null | IPILIMUMAB | 100748570 |
| 10418509 | 10041284 | null | null | Curative (C) | 2018-03-08 | 2018-03-08 | IDELALISIB + RITUXIMAB | 02 | null | CTD | 101204312 |
| 10418547 | 10041285 | 1.72 | 61.7 | Curative (C) | 2020-01-06 | 2020-01-22 | CISPLATIN + ETOPOSIDE | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101552694 |
| 10418578 | 10041287 | 1.7 | 67.3 | Palliative (P) | 2018-06-05 | 2018-07-15 | Cisplatin+Doxorubicin+Etoposide 28d | 02 | N | CISPLATIN + RT | 100713107 |
| 10418659 | 10041289 | 1.76 | 73.5 | Curative (C) | 2016-11-21 | 2016-11-21 | Sorafenib | null | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100645668 |
| 10418665 | 10041290 | 1.73 | 76 | Curative (C) | 2018-12-01 | 2018-12-04 | GEMCITABINE + NAB PACLITAXEL | 02 | N | OFATUMUMAB | 100132250 |
| 10418689 | 10041291 | 1.66 | 53.2 | Palliative (P) | 2018-12-30 | 2018-12-30 | Cisplatin + Pemetrexed | 02 | N | CAPECITABINE + RT | 100930336 |
| 10418705 | 10041292 | 1.8 | 87.5 | 03 | 2017-08-04 | 2017-08-09 | CHLVPP | 02 | N | MYELOMA XII TRIAL | 101159646 |
| 10418708 | 10041293 | 1.61 | 72.5 | Curative (C) | 2020-01-25 | 2020-02-01 | CAPECITABINE + PACLITAXEL | 02 | N | ABEMACICLIB + FULVESTRANT | 101474584 |
| 10418740 | 10041295 | null | 79 | null | 2019-06-22 | 2019-06-24 | null | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100832969 |
| 10418772 | 10041298 | null | null | 03 | 2019-05-15 | 2019-05-16 | CHOEP | 02 | null | CYCLOPHOSPHAMIDE HIGH DOSE | 100154106 |
| 10418774 | 10041299 | null | 0 | Disease modification (D) | 2018-06-01 | 2018-06-08 | Bortezomib + Cyclophos + Dex | N | N | SORAFENIB | 101828551 |
| 10418791 | 10041300 | 1.6 | 67.7 | Neo-adjuvant (N) | 2017-10-26 | 2017-10-26 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | RIALTO TRIAL | 100005370 |
| 10418970 | 10041303 | 1.8 | 60 | Palliative (P) | 2019-10-04 | 2019-10-04 | CYCLOPHOSPHAMIDE + IDARUBICIN | 02 | null | OSIMERTINIB | 100405748 |
| 10419025 | 10041304 | null | null | 03 | 2019-04-21 | 2019-04-23 | Methotrexate intrathecal | 02 | N | ANAGRELIDE | 100296097 |
| 10419072 | 10041305 | 1.72 | 69.8 | Neo-adjuvant (N) | 2017-08-13 | 2017-08-13 | Cisplatin + Etoposide po | 02 | N | NILOTINIB | 100593677 |
| 10419090 | 10041306 | 1.8 | null | Palliative (P) | 2019-11-14 | 2019-11-14 | Atezolizumab | 02 | N | SORAFENIB | 100035807 |
| 10419147 | 10041307 | 1.6 | null | Curative (C) | 2019-04-17 | 2019-04-17 | BLEOMYCIN | 02 | null | DOXORUBICIN | 100712481 |
| 10419189 | 10041308 | 1.67 | 72 | null | null | 2020-06-08 | null | N | N | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 101301716 |
| 10419200 | 10041309 | 1.7 | 78.4 | Palliative (P) | null | 2020-01-02 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | null | null | BORTEZOMIB + MELPHALAN | 100871374 |
| 10419318 | 10041311 | 1.59 | 90.3 | Curative (C) | 2017-02-22 | 2017-02-22 | null | 02 | N | DOXORUBICIN + OLARATUMAB | 101739555 |
| 10419429 | 10041313 | 1.75 | 91 | 03 | 2019-05-10 | 2019-06-04 | CAPECITABINE + CARBOPLATIN | 02 | N | CTD | 100877458 |
| 10419533 | 10041316 | 1.84 | 54.5 | Curative (C) | 2018-06-15 | 2018-07-04 | Letrozole + Palbociclib | 02 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100711038 |
| 10419559 | 10041317 | 1.69 | 82.4 | null | 2020-04-03 | 2020-05-08 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | BLEOMYCIN | 101089444 |
| 10419776 | 10041321 | 1.66 | 60.6 | Palliative (P) | 2020-01-25 | 2020-01-28 | AFATINIB | 2 | N | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100659154 |
| 10419891 | 10041323 | 1.86 | 128 | null | 2020-06-05 | 2020-06-05 | Oxaliplatin + Modified de Gramont | 2 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100735357 |
| 10419908 | 10041324 | 1.7 | 69 | Neo-adjuvant (N) | 2020-10-06 | 2020-10-06 | Binimetinib + Encorafenib | 2 | N | IRINOTECAN + MDG | 101392831 |
| 10420033 | 10041326 | null | null | 03 | 2020-02-03 | 2020-02-09 | DA 3 + 10 | 02 | null | CARBOPLATIN + LIPOSOMAL DOXORUBICIN | 100659919 |
| 10420089 | 10041327 | 1.69 | 68 | null | 2022-03-08 | 2022-03-25 | Bortezomib + Cyclophos + Dex | N | null | OBINUTUZUMAB + VENETOCLAX | 100111894 |
| 10420102 | 10041328 | 1.63 | 65.6 | null | 2019-05-14 | 2019-05-22 | DAUNORUBICIN + VINCRISTINE | 02 | null | PACLITAXEL + TRASTUZUMAB | 100241314 |